Author: Adela Farre

Bionure has launched today a crowdfunding campaign through the Spanish platform of Capital Cell (capitalcel.es) with the objective of raising €1.3M that will be used to finance the preparation of the phase 2 study of its neuroprotectant BN201....

Bionure, a biotech company specialized in neuroprotection, today announces that it has appointed Dr. Lucia Septien as chief medical officer. Dr. Septien joins Bionure at a crucial time, as the company is preparing for a phase 2 clinical study with its lead compound, BN201....